Drugs / GATAPARSEN
GATAPARSEN
also known as
LY2181308 · GATAPARSEN SODIUM · LY-2181308 HEPTADECASODIUM SALT · LY2181308 sodium · sodium LY2181308
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00415155 | Aug 2008 → Jan 2011 | hepatocellular carcinoma | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01107444 | May 2010 → Dec 2011 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00642018 | Mar 2008 → Aug 2011 | prostate cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00620321 | Mar 2008 → Jan 2010 | acute myeloid leukemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GATAPARSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | GATAPARSEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | LY-2181308 HEPTADECASODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | LY2181308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00415155 ↗ |
| Known as | LY2181308 sodium | “LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days.” NCT00642018 ↗ |
| Known as | sodium LY2181308 | “The antisense oligonucleotide sodium LY2181308 (LY2181308) inhibits survivin expression and may cause cell cycle arrest and restore apoptosis in AML.” PMID 23397500 ↗ Feb 2013 |
| Action | Inhibit | “inhibits survivin expression” PMID 23397500 ↗ Feb 2013 |
| Modality | Antisense oligonucleotide | “Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308” PMID 23397500 ↗ Feb 2013 |
| Route | Intravenous | “250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.” NCT00415155 ↗ |